Dr. Reddy's Laboratories faces a deteriorating fundamental picture with declining revenue of 12% year-over-year, two consecutive earnings misses, a death cross blocking entry, and the stock already priced above analyst targets — making the current setup one of the weakest risk-reward profiles in the healthcare sector despite reasonable absolute valuation multiples.
Thesis pillars
- Revenue Decline And Miss Pattern→Stable
- Death Cross And Negative Asymmetry→Stable
- Extreme Put Call Ratio→Stable
- +1 more pillar — see the Why tab for full reasoning
Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis
Momentum Cont setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $14.64 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and... Read more
Sell if holding. Analyst target reached at $14.64 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Trend continuation, RSI 64, MACD bullish. Score 4.2/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-07-07Recent Developments — Dr. Reddy's Laboratories Ltd
Latest news
- NEWS Dr. Reddy's Laboratories Ltd (RDY) Releases Q4 2026 Earnings: Revenue and Profits Plunge, Margins Compressed - Quiver Qu — Quiver Quantitative negative
- NEWS Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss - GuruFocus — GuruFocus negative
- NEWS Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY) - Seeking Alpha — Seeking Alpha positive
- NEWS Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS — AD HOC NEWS neutral
- NEWS Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday - MarketBeat — MarketBeat neutral
Generated 2026-07-07T15:32:22Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -11.6% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $14.64 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Trend continuation, RSI 64, MACD bullish. Prior stop was $13.73. Score 4.2/10, moderate confidence.
Take-profit target: $15.36 (+5.4% upside). Prior stop was $13.73. Stop-loss: $13.73.
Analyst target reached - limited upside remaining; Consecutive earnings misses (2); Weak overall score: 4.2/10.
Dr. Reddy's Laboratories Ltd trades at a P/E of 26.1 (forward 21.7). TrendMatrix value score: 6.0/10. Verdict: Sell.
44 analysts cover RDY with a consensus score of 3.4/5. Average price target: $14.
What does Dr. Reddy's Laboratories Ltd do?Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company...
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.